Skip to main content

Table 1 Histone methyltransferase inhibitors reduce transformation of HBECs in conjunction with reprogramming of the transcription

From: Chromatin remodeling by the histone methyltransferase EZH2 drives lung pre-malignancy and is a target for cancer prevention

Cell line Treatment Transformationa 50–100%  > 100% Total
(% Reduction) (Change in expression # genes)
HBEC2T DZNep 80 ± 2 1675 976 2651
  EPZ6438 70 ± 3 328 160 488
  UNC0642 0 85 23 108
  EPZ/UNC 70 ± 4 574 323 897
  Lovaza 30 ± 3 20 2 22
HBEC13T DZNep 80 ± 3 838 332 1170
  EPZ6438 0 211 76 287
  UNC0642 0 80 25 153
  EPZ/UNC 48 ± 4 265 109 374
  Lovaza 28 ± 3 22 1 23
  1. aMean ± SD % reduction in transformation from triplicate soft agar assays compared to vehicle